Maribavir for kids with CMV after transplant
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 18 years old, and a parent/guardian must consent and the child should assent when appropriate
- You must have had a functioning transplant (either stem cell transplant or solid organ transplant) at screening
- You must have CMV infection confirmed by blood tests that meet specific “virus level” thresholds on two tests
- Blood and kidney tests must be high enough (neutrophils, platelets, hemoglobin, and kidney function)
- You must test negative for HIV within 3 months of starting the study
- You must be able to take the study medicine by mouth and follow study rules for about 8 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
This study tests a new medicine called maribavir for Chinese adults who have a CMV infection that hasn't gotten better with standard treatments. It may be an option for transplant recipients who need a different approach.
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
This study tests a medication called LIVTENCITY (maribavir) for adults in South Korea who have a CMV infection after a transplant. It is for people whose infection has not improved or has become resistant to other antiviral medicines.
This study tests a medicine called maribavir for people who have a CMV infection after a stem cell transplant. It watches how well the medicine works and how safe it is.
Hear when a new Cytomegalovirus (CMV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.